Αποτελέσματα Αναζήτησης
Our case illustrates an example of the successful use of FFP for the treatment of life-threatening ACE-IAE refractory to conventional therapy. Physicians treating patients presenting with severe ACE-IAE should keep this treatment in mind when steroids, antihistamines, and epinephrine fail to reverse symptoms.
5 Μαρ 2024 · Benefits of fresh frozen plasma. Treatment options for bradykinin-mediated angioedema range from a C1-esterase inhibitor concentrate (C1-INH), which contain a working version of the protein of the same name, to medications that block the action of kallikrein or bradykinin.
3 Φεβ 2016 · Fresh frozen plasma (FFP) is one treatment option for acute bradykinin-induced AE with airway compromise. The first report of its successful use was in hereditary AE in 1969 . Subsequent case reports have demonstrated the effectiveness of FFP (given within 45 minutes to 12 hours) for both HAE and non-HAE [7, 8].
11 Αυγ 2020 · This is the first time the successful treatment of hereditary angioedema with FFP has been reported from Pakistan. In the absence of targeted therapy in most LMICs, FFP is an alternative therapeutic option for the acute management of HAE.
Why Do You Give FFP For Angioedema? Fresh-frozen plasma from a healthy donor contains the C1 inhibitor that is lacking or dysfunctional in someone with hereditary angioedema. Transfusions of FFP can help reduce excess bradykinin in the blood of someone with hereditary angioedema, preventing or treating acute attacks.
The key findings of our study include: (1) FFP is effective, although the time-to-resolution is considerably slower than reported for targeted therapies; (2) FFP has a TEAE rate of ~5%, and premedication may reduce TEAEs; (3) setting-specific differences in acute HAE management and FFP use exist including speed of access to FFP therapy ...
In the treatment of ACE-I angioedema, FFP might provide further kininase II, which breaks down accumulated bradykinin, and might also provide functional enzyme in those patients with enzyme defects in bradykinin metabolism.
